

François Curtin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4583445/publications.pdf>

Version: 2024-02-01

37
papers

3,348
citations

331670

21
h-index

330143

37
g-index

37
all docs

37
docs citations

37
times ranked

3135
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study. <i>Multiple Sclerosis Journal</i> , 2022, 28, 429-440.	3.0	40
2	Impact of Acute Inflammation on Cytochromes P450 Activity Assessed by the Geneva Cocktail. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1668-1676.	4.7	42
3	Impact of SARS-CoV-2 Infection (COVID-19) on Cytochromes P450 Activity Assessed by the Geneva Cocktail. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1358-1367.	4.7	36
4	Genetic Susceptibility Toward Nausea and Vomiting in Surgical Patients. <i>Frontiers in Genetics</i> , 2021, 12, 816908.	2.3	1
5	Temelimab, an IgG4 Anti-Human Endogenous Retrovirus Monoclonal Antibody: An Early Development Safety Review. <i>Drug Safety</i> , 2020, 43, 1287-1296.	3.2	12
6	GABAergic modulation of secondary hyperalgesia: A randomized controlled 4-way crossover trial with the $\alpha 2$ subunit preferring GABA positive allosteric modulator, <i>desmethylnaloxonium</i> in healthy volunteers. <i>European Journal of Pain</i> , 2020, 24, 1094-1106.	2.8	3
7	A safety and pharmacodynamics study of temelimab, an antipathogenic human endogenous retrovirus type W envelope monoclonal antibody, in patients with type 1 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1111-1121.	4.4	9
8	A High-dose Pharmacokinetic Study of a New IgG4 Monoclonal Antibody Temelimab/GN β AC1 Antagonist of an Endogenous Retroviral Protein pHERV-W Env. <i>Clinical Therapeutics</i> , 2019, 41, 1737-1746.	2.5	10
9	Prevention of clinical and histological signs of MOG-induced experimental allergic encephalomyelitis by prolonged treatment with recombinant human EGF. <i>Journal of Neuroimmunology</i> , 2019, 332, 224-232.	2.3	29
10	Corrections to effect size variances for continuous outcomes of crossover clinical trials. <i>Statistics in Medicine</i> , 2018, 37, 320-323.	1.6	8
11	A new therapeutic approach for type 1 diabetes: Rationale for GN β AC1, an anti-HERV-W Env monoclonal antibody. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2075-2084.	4.4	32
12	Meta-analysis combining parallel and crossover trials with random effects. <i>Research Synthesis Methods</i> , 2017, 8, 263-274.	8.7	10
13	The role of adaptive trial designs in drug development. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 727-736.	3.1	14
14	Meta-analysis combining parallel and crossover trials using generalised estimating equation method. <i>Research Synthesis Methods</i> , 2017, 8, 312-320.	8.7	5
15	Human Endogenous Retrovirus and Neuroinflammation in Chronic Inflammatory Demyelinating Polyradiculoneuropathy. <i>EBioMedicine</i> , 2016, 6, 190-198.	6.1	30
16	Serum pharmacokinetics and cerebrospinal fluid concentration analysis of the new IgG4 monoclonal antibody GN β AC1 to treat multiple sclerosis: A Phase 1 study. <i>MABs</i> , 2016, 8, 854-860.	5.2	18
17	A placebo randomized controlled study to test the efficacy and safety of GN β AC1, a monoclonal antibody for the treatment of multiple sclerosis – Rationale and design. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 9, 95-100.	2.0	15
18	MSRV envelope protein is a potent, endogenous and pathogenic agonist of human toll-like receptor 4: Relevance of GN β AC1 in multiple sclerosis treatment. <i>Journal of Neuroimmunology</i> , 2016, 291, 29-38.	2.3	70

#	ARTICLE	IF	CITATIONS
19	Immunologic monitoring during a phase 2a trial of the GNBAC1 antibody in patients with MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e144.	6.0	16
20	A phase IIa randomized clinical study testing GNBAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis associated endogenous retrovirus in multiple sclerosis patients – A twelve month follow-up. <i>Journal of Neuroimmunology</i> , 2015, 285, 68-70.	2.3	41
21	Preclinical and early clinical development of GNBAC1, a humanized IgG4 monoclonal antibody targeting endogenous retroviral MSRV-Env protein. <i>MAbs</i> , 2015, 7, 265-275.	5.2	68
22	Treatment Against Human Endogenous Retrovirus: A Possible Personalized Medicine Approach for Multiple Sclerosis. <i>Molecular Diagnosis and Therapy</i> , 2015, 19, 255-265.	3.8	16
23	A phase IIa randomised clinical study of GNBAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2015, 21, 885-893.	3.0	53
24	Novel therapeutic options for multiple sclerosis. <i>Expert Review of Clinical Pharmacology</i> , 2014, 7, 91-104.	3.1	22
25	Benefit-Risk of Immunomodulators in Multiple Sclerosis. Alemtuzumab and Next?. <i>Journal of Neurology & Neurophysiology</i> , 2014, 05, .	0.1	1
26	The DNA Copy Number of Human Endogenous Retrovirus-W (MSRV-Type) Is Increased in Multiple Sclerosis Patients and Is Influenced by Gender and Disease Severity. <i>PLoS ONE</i> , 2013, 8, e53623.	2.5	64
27	Psychological distress in fibromyalgia patients: A role for catechol-O-methyl-transferase Val158met polymorphism.. <i>Health Psychology</i> , 2012, 31, 242-249.	1.6	42
28	GNBAC1, a Humanized Monoclonal Antibody Against the Envelope Protein of Multiple Sclerosis-associated Endogenous Retrovirus: A First-in-Humans Randomized Clinical Study. <i>Clinical Therapeutics</i> , 2012, 34, 2268-2278.	2.5	68
29	Rapid benefits of a new formulation of subcutaneous interferon beta-1a in relapsing/remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2010, 16, 888-892.	3.0	31
30	Clonazepam and lorazepam in acute mania: a Bayesian meta-analysis. <i>Journal of Affective Disorders</i> , 2004, 78, 201-208.	4.1	54
31	Moclobemide discontinuation syndrome predominantly presenting with influenza-like symptoms. <i>Journal of Psychopharmacology</i> , 2002, 16, 271-272.	4.0	13
32	Meta-analyses involving cross-over trials: methodological issues. <i>International Journal of Epidemiology</i> , 2002, 31, 140-149.	1.9	1,999
33	Meta-analysis combining parallel and cross-over clinical trials. I: Continuous outcomes. <i>Statistics in Medicine</i> , 2002, 21, 2131-2144.	1.6	192
34	Meta-analysis combining parallel and cross-over clinical trials. II: Binary outcomes. <i>Statistics in Medicine</i> , 2002, 21, 2145-2159.	1.6	113
35	Meta-analysis combining parallel and cross-over clinical trials. III: The issue of carry-over. <i>Statistics in Medicine</i> , 2002, 21, 2161-2173.	1.6	112
36	Relation of BMI to a dual-energy X-ray absorptiometry measure of fatness. <i>British Journal of Nutrition</i> , 1999, 82, 49-55.	2.3	49

#	ARTICLE	IF	CITATIONS
37	Psychosocial Profile of Swiss Sexual Offenders. Journal of Forensic Sciences, 1998, 43, 755-759.	1.6	10